Prediction and confirmation of the presence of disease-related miRNAs is beneficial to understand disease mechanisms at the miRNA level. However, the use of experimental verification to identify disease-related miRNAs is expensive and time-consuming. Effective computational approaches used to predict miRNA-disease associations are highly specific. In this study, we develop the Network Consistency Projection for miRNA-Disease Associations (NCPMDA) method to reveal the potential associations between miRNAs and diseases. NCPMDA is a non-parametric universal network-based method that can simultaneously predict miRNA-disease associations in all diseases but does not require negative samples. NCPMDA can also confirm the presence of miRNAs in isolated diseases (diseases without any known miRNA association). Leave-one-out cross validation and case studies have shown that the predictive performance of NCPMDA is superior over that of previous method.

There is more and more evidence that the mutation and dysregulation of long non-coding RNA (lncRNA) are associated with numerous diseases, including cancers. However, experimental methods to identify associations between lncRNAs and diseases are expensive and time-consuming. Effective computational approaches to identify disease-related lncRNAs are in high demand; and would benefit the detection of lncRNA biomarkers for disease diagnosis, treatment, and prevention. In light of some limitations of existing computational methods, we developed a global network random walk model for predicting lncRNA-disease associations (GrwLDA) to reveal the potential associations between lncRNAs and diseases. GrwLDA is a universal network-based method and does not require negative samples. This method can be applied to a disease with no known associated lncRNA (isolated disease) and to lncRNA with no known associated disease (novel lncRNA). The leave-one-out cross validation (LOOCV) method was implemented to evaluate the predicted performance of GrwLDA. As a result, GrwLDA obtained reliable AUCs of 0.9449, 0.8562, and 0.8374 for overall, novel lncRNA and isolated disease prediction, respectively, significantly outperforming previous methods. Case studies of colon, gastric, and kidney cancers were also implemented, and the top 5 disease-lncRNA associations were reported for each disease. Interestingly, 13 (out of the 15) associations were confirmed by literature mining.

In recent years, it has been increasingly clear that long noncoding RNAs (lncRNAs) play critical roles in many biological processes associated with human diseases. Inferring potential lncRNA-disease associations is essential to reveal the secrets behind diseases, develop novel drugs, and optimize personalized treatments. However, biological experiments to validate lncRNA-disease associations are very time-consuming and costly. Thus, it is critical to develop effective computational models. In this study, we have proposed a method called BPLLDA to predict lncRNA-disease associations based on paths of fixed lengths in a heterogeneous lncRNA-disease association network. Specifically, BPLLDA first constructs a heterogeneous lncRNA-disease network by integrating the lncRNA-disease association network, the lncRNA functional similarity network, and the disease semantic similarity network. It then infers the probability of an lncRNA-disease association based on paths connecting them and their lengths in the network. Compared to existing methods, BPLLDA has a few advantages, including not demanding negative samples and the ability to predict associations related to novel lncRNAs or novel diseases. BPLLDA was applied to a canonical lncRNA-disease association database called LncRNADisease, together with two popular methods LRLSLDA and GrwLDA. The leave-one-out cross-validation areas under the receiver operating characteristic curve of BPLLDA are 0.87117, 0.82403, and 0.78528, respectively, for predicting overall associations, associations related to novel lncRNAs, and associations related to novel diseases, higher than those of the two compared methods. In addition, cervical cancer, glioma, and non-small-cell lung cancer were selected as case studies, for which the predicted top five lncRNA-disease associations were verified by recently published literature. In summary, BPLLDA exhibits good performances in predicting novel lncRNA-disease associations and associations related to novel lncRNAs and diseases. It may contribute to the understanding of lncRNA-associated diseases like certain cancers.

Identification of miRNA-disease association is a fundamental challenge in human health clinic. However, the known miRNA-disease associations are rare and experimental verification methods are expensive and time-consuming. Therefore, there is a strong incentive to develop computational methods. In this paper, we calculate the similarity score for each miRNAs pair by integrating miRNA functional similarity and miRNA family information. We use the disease phenotype similarity data to construct the disease similarity network. Then we introduce a new miRNA-disease association prediction method (NETwork Group Similarity, NetGS) to explore the global network similarity, capturing the relationship between the disease and other diseases, the similarity between the potential disease-related miRNA and other miRNAs. Finally based on the consistency of diffusion profiles we get the miRNA-disease association scores. NetGS is tested by the leave-one-out cross validation and achieves an AUC value of 0.8450, which improves the prediction accuracy. NetGS can also be applied to solve the new miRNA-disease association and obtain reliable accuracy. Moreover, we use NetGS to predict new causing miRNAs of three cancers including breast cancer, lung cancer and Hepatocellular cancer. And the top predictions have been confirmed in the online databases. The encouraging results indicate that NetGS might play an essential role for future scientific research.

According to the miRNA and disease similarity network, the unknown associations are predicted by combining the known miRNA-disease association network based on collaborative filtering recommendation algorithm.

Floating car data are beneficial in estimating traffic conditions in wide areas and are playing an increasing role in traffic surveillance. However, widespread application is limited by low-sample frequency which makes it hard to get a complete picture of a vehicle’s motion. An accurate and reliable reconstruction of a vehicle’s trajectory could effectively result in a higher sampling frequency enabling a more accurate estimation of road traffic parameters. Existing methods require additional information such as nearby vehicles, signal timing strategies, and queue patterns which are not always available. To address this problem, this paper presents a method used with low-sample frequency data to reconstruct vehicle trajectories through intersections, without the need for extra information. Furthermore, the additional parameters for the speed-time curve distributions for deceleration rate and acceleration rate are generated. A piecewise deceleration and acceleration model is developed to calculate the acceleration rate for different travel modes in the trajectory. The distribution parameters of the acceleration data for each travel mode are then estimated using a new Expectation Maximization (EM) algorithm. The acceleration statistics are then used to reconstruct the corresponding parts of the trajectory. Compared to the reference trajectories (truth), the test results show that the method developed in this paper achieves improvement in accuracy ranging from 16 to 67% over the commonly used linear interpolation method. In addition, the proposed method is not very sensitive to the sampling interval of the floating car data, unlike the linear interpolation method where the error grows rapidly with increasing sampling interval.

The classification of tumors is crucial for the proper treatment of cancer. Sparse representation-based classifier (SRC) exhibits good classification performance and has been successfully used to classify tumors using gene expression profile data. In this study, we propose a three-step maxdenominator reweighted sparse representation classification (MRSRC) method to classify tumors. First, we extract a set of metagenes from the training samples. These metagenes can capture the structures inherent to the data and are more effective for classification than the original gene expression data. Second, we use a reweighted regularization method to obtain the sparse representation coefficients. Reweighted regularization can enhance sparsity and obtain better sparse representation coefficients. Third, we classify the data by utilizing a maxdenominator residual error function. Maxdenominator strategy can reduce the residual error and improve the accuracy of the final classification. Extensive experiments using publicly available gene expression profile data sets show that the performance of MRSRC is comparable with or better than many existing representative methods.

Background Many long non-coding RNAs (lncRNAs) have key roles in different human biologic processes and are closely linked to numerous human diseases, according to cumulative evidence. Predicting potential lncRNA-disease associations can help to detect disease biomarkers and perform disease analysis and prevention. Establishing effective computational methods for lncRNA-disease association prediction is critical. Results In this paper, we propose a novel model named MAGCNSE to predict underlying lncRNA-disease associations. We first obtain multiple feature matrices from the multi-view similarity graphs of lncRNAs and diseases utilizing graph convolutional network. Then, the weights are adaptively assigned to different feature matrices of lncRNAs and diseases using the attention mechanism. Next, the final representations of lncRNAs and diseases is acquired by further extracting features from the multi-channel feature matrices of lncRNAs and diseases using convolutional neural network. Finally, we employ a stacking ensemble classifier, consisting of multiple traditional machine learning classifiers, to make the final prediction. The results of ablation studies in both representation learning methods and classification methods demonstrate the validity of each module. Furthermore, we compare the overall performance of MAGCNSE with that of six other state-of-the-art models, the results show that it outperforms the other methods. Moreover, we verify the effectiveness of using multi-view data of lncRNAs and diseases. Case studies further reveal the outstanding ability of MAGCNSE in the identification of potential lncRNA-disease associations. Conclusions The experimental results indicate that MAGCNSE is a useful approach for predicting potential lncRNA-disease associations.